Thursday, October 15, 2026

Coffee Futures Is 11% Down In The Last 10 Sessions

Coffee Futures Is 11% Down In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 11.96% for the last 10 sessions. At 05:51 EST on Friday, 3 May, Coffee (KC) is $204.30.

Volume

Today's last reported volume for Coffee is 2603, 87.6% below its average volume of 20998.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was 0.14%, 0.23%, and 2.95%, respectively.

Coffee's highest amplitude of average volatility was 2.18% (last week), 1.89% (last month), and 2.95% (last quarter), respectively.

News about

  • Crude oil recedes post-fed, WTI tumbles below $80. According to FXStreet on Wednesday, 1 May, "This week's EIA print represents the highest WoW Crude Oil buildup since the week ended February 9. ", "With most global markets focused on the Fed's latest rate call, the Energy Information Administration (EIA) printed its latest week-on-week barrel counts for US Crude Oil supply. "
  • According to FXStreet on Thursday, 2 May, "The Mexican Peso (MXN) trades higher in its key pairs on Thursday as market sentiment gets a lift from a combination of factors, including the US Federal Reserve's (Fed) decision to maintain an easing bias at its policy meeting on Wednesday, and Crude Oil prices hovering close to seven-week lows.", "Lower Crude Oil prices, with WTI trading in the mid $79s, were a further positive factor for global risk sentiment as they reduce companies' transportation and energy costs."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Coffee Futures Is 11% Down In The Last 10 Sessions | Via News